Poolbeg Pharma PLC Announces Result of AGM
Poolbeg Pharma, a UK-based biopharmaceutical company, announced that all resolutions presented at their Annual General Meeting on June 17, 2024, were approved by shareholders. The company, traded under AIM:POLB and OTCQB:POLBF, focuses on developing and commercializing innovative medicines for diseases with high unmet medical needs. This successful AGM marks a positive step for Poolbeg as they continue their mission to address critical health challenges.
- All resolutions at the AGM were approved by shareholders.
- Poolbeg Pharma continues to focus on developing medicines for diseases with high unmet medical needs.
- The successful AGM suggests shareholder confidence in the company's direction and strategies.
- The press release lacks specific financial data, clinical updates, or future business strategies which are critical for detailed investor analysis.
Results of Annual General Meeting
LONDON, UNITED KINGDOM / ACCESSWIRE / June 17, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ‘Poolbeg' or the ‘Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that all resolutions put to shareholders at the Company's Annual General Meeting held earlier today were duly passed.
Enquiries
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O'Connell, CFO | +44 (0) 207 183 1499 |
Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker) Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM) | +44 (0) 207 220 0500 |
Shore Capital Stockbrokers Ltd (Joint Broker) David Coaten, Harry Davies-Ball (Corporate Advisory), Malachy McEntyre, Isobel Jones (Corporate Broking) | +44 (0) 207 408 4090 |
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist | +353 (0) 1 679 6363 |
Optimum Strategic Communications Nick Bastin, Vici Rabbetts, Elena Bates
| +44 (0) 208 078 4357 |
About Poolbeg Pharma
Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues.
Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.
For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Poolbeg Pharma PLC
View the original press release on accesswire.com
FAQ
What was the outcome of Poolbeg Pharma's AGM held on June 17, 2024?
What is Poolbeg Pharma's stock symbol?
What is the focus of Poolbeg Pharma?